Citations

Showing 10 of 108104 citations.

CD38 inhibitor 78c increases mice lifespan and healthspan in a model of chronological aging
Thompson, Katie L., Warner, Gina M., Chini, Claudia C.S. , Tarragó, Mariana G., Mazdeh, Delaram Z., Zhang, Chunlian , Zavala‐Solorio, Jose , Kolumam, Ganesh , Wong, Yao Liang , Cohen, Robert L. , Chini, Eduardo N. , Peclat, Thais R , Liang Wong, Yao , Chini, Eduardo Nunes , Peclat, Thais

Mayo Clinic

Aging Cell | March 8, 2022 | Volume: 21 | Issue: 4 | Pages: No page available

10.1111/acel.13589 | PMID 35263032 Get It

Abstract Nicotinamide adenine dinucleotide (NAD) levels decline during aging, contributing to physical and metabolic dysfunction. The NADase CD38 plays a key role in age‐related NAD decline. Whether the inhibition of CD38 increases lifespan is not known. Here, we show that the CD38 inhibitor 78c increases lifespan and healthspan of naturally aged mice. In addition to a 10% increase in median survival, 78c improved exercise performance, endurance, and metabolic function in mice. The effects of 78c were different between sexes. Our study is the first to investigate the effect of CD38 inhibition in naturally aged animals.
Abstract GS1-07: Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial
Frantal, Sophie, Burstein, H.J., Greil, Richard , Winer, Eric, Singer, Christian, Miller, Kathy L. , Naughton, Michelle J. , Bliss, Judith M. , Steger, Guenther G. , Nowecki, Zbigniew , Hahn, Olwen, Rugo, Hope, Pfeiler, Georg , Fohler, Hannes, Schurmans, Céline , Theall, K. P., Lu, Dongrui R. , Tenner, Kathleen , Fesl, Christian , authorship, *shared last, Bliss, Judith , Gnant, Michael , Dueck, Amylou C. , Martín, Miguel , Fox, Peter , Wolff, Antonio C. , Chan, Arlene , Colleoni, Marco , Rubovsky, Gabor , Mayer, Ingrid A. , Wolmark, Norman , Metzger, Otto , DeMichele, Angela , Mayer, Erica L. , authorship, *shared last

Mayo Clinic

Cancer Research | March 8, 2022 | Volume: 82 | Issue: 4_Supplement | Pages: GS1-07-GS1-07

10.1158/1538-7445.sabcs21-gs1-07 Get It

Abstract Background Advances in the multidisciplinary care of hormone-receptor positive (HR+) early breast cancer (eBC) have markedly improved clinical outcomes: however, disease recurrence may still occur, particularly in patients (pts) with moderate or high-risk cancers at the time of diagnosis. The use of CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) is a standard of care for advanced breast cancer, supporting the rationale to study CDK4/6i in the eBC setting. Here we present the final protocol-planned analyses of the global phase III PALLAS trial investigating whether the addition of the CDK4/6i palbociclib (P) to adjuvant ET improves outcomes over ET alone for HR+/HER2- eBC. Methods PALLAS (PALbociclib CoLlaborative Adjuvant Study, NCT02513394) is a randomized phase III open-label trial in which pts with stage II-III HR+/HER2- eBC were randomized to receive either 2 years of P with adjuvant ET (P+ET) or ET alone. The primary endpoint is invasive disease-free survival (iDFS); secondary endpoints include distant recurrence-free survival (DRFS), locoregional recurrence-free survival (LRRFS), overall survival (OS), and safety. Mandatory biospecimen collection has supported the creation of an expansive translational science program, and long-term follow-up is planned. Revised sample size calculations required recruitment of 5600 pts in order to detect a 25% iDFS improvement in patients receiving P+ET with 85% power; this final protocol-planned analysis was planned after 469 iDFS events. Results From September 1, 2015 to November 30, 2018, 5,761 pts (median age 52 years, range 22-90) were randomized in 406 centers in 21 countries worldwide. 1,014 (17.6%) had stage IIA disease (capped) and 4,728 (82.1%) stages IIB/III. 4,754 (82.5%) had received prior (neo)adjuvant chemotherapy. After a protocol-planned 2nd interim analysis in May 2020 crossed the futility threshold, 349 P+ET pts still on active treatment stopped P and were transferred to follow-up. At the time of final analysis cutoff date (November 20, 2020), after a median follow-up of 31 months and 516 events recorded, iDFS was similar between the two arms, with 3-year iDFS of 89.3% (95% CI: 87.8-90.6%) for Palbo+ET, and 89.4% (88.0-90.7%) for ET alone (hazard ratio 0.96, 95% CI: 0.81-1.14). There was no statistically significant difference in secondary outcome endpoints. Subgroup analyses revealed no significant interactions between treatment effect and other factors (including risk category). The safety profile of P was as expected, with grade 3 or 4 neutropenia the most common side effect (safety population: 1759/2841 [61.9%] vs 11/2902 [0.4%]). Overall 42% of pts. discontinued P prior to the planned 2-year duration, 28.2% of Palbo+ET pts discontinued therapy due to adverse events, without an observed impact on survival outcomes. Conclusions Now with the full number of events, this analysis of the PALLAS trial shows that the addition of 2 years of P to ongoing adjuvant ET did not improve survival endpoints for pts with stage II-III HR+/HER2- eBC. Whether P is beneficial in the adjuvant setting for certain sub-groups of pts will be further evaluated with longer-term follow-up and by the ongoing translational science program. Support: ABCSG; AFT; Pfizer; ClinicalTrials.gov Identifier: NCT02513394; https://www.abcsg.org; https://acknowledgments.alliancefound.org Citation Format: Michael Gnant, Amylou C Dueck, Sophie Frantal, Miguel Martin, Hal Burstein, Richard Greil, Peter Fox, Antonio C Wolff, Arlene Chan, Eric Winer, Christian Singer, Kathy Miller, Marco Colleoni, Michelle Naughton, Gabor Rubovszky, Judith Bliss, Ingrid A Mayer, Guenther G Steger, Zbigniew Nowecki, Olwen Hahn, Norman Wolmark, Hope Rugo, Georg Pfeiler, Hannes Fohler, Otto Metzger, Céline Schurmans, Kathy P Theall, Dongrui R Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele*, Erica L Mayer, *shared last authorship. Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr GS1-07.
Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer
Zhang, Yixiao, Sun, Lisha , Li, Haonan, Ai, Liping, Ma, Qingtian, Qiao, Xinbo , Yang, Jie, Zhang, Hao, Ou, Xunyan, Wang, Yining, Chen, Guanglei, Xue, Jinqi, Zhu, Xudong, Zhao, Yu, Yang, Yongliang, Liu, Caigang , Zhu, Xudong , Zhang, Yixiao, Sun, Lisha , Li, Haonan, Ai, Liping, Ma, Qingtian, Qiao, Xinbo , Yang, Jie, Zhang, Hao, Ou, Xunyan, Wang, Yining, Chen, Guanglei, Xue, Jinqi, Zhu, Xudong, Zhao, Yu, Yang, Yongliang, Liu, Caigang

Mayo Clinic

eLife | March 8, 2022 | Volume: 11 | Issue: No issue available | Pages: No page available

10.7554/elife.68481 | PMID 35285795 Get It

Background: Integrin family are known as key gears in focal adhesion for triple-negative breast cancer (TNBC) metastasis. However, the integrin independent factor TLN1 remains vague in TNBC. Methods: Bioinformatics analysis was performed based on TCGA database and Shengjing Hospital cohort. Western blot and RT-PCR were used to detect the expression of TLN1 and integrin pathway in cells. A small-molecule C67399 was screened for blocking TLN1 and integrin β1 through a novel computational screening approach by targeting the protein-protein binding interface. Drug pharmacodynamics were determined through xenograft assay. Results: Upregulation of TLN1 in TNBC samples correlates with metastasis and worse prognosis. Silencing TLN1 in TNBC cells significantly attenuated the migration of tumour cells through interfering the dynamic formation of focal adhesion with integrin β1, thus regulating FAK-AKT signal pathway and epithelial-mesenchymal transformation. Targeting the binding between TLN1 and integrin β1 by C67399 could repress metastasis of TNBC. Conclusions: TLN1 overexpression contributes to TNBC metastasis and C67399 targeting TLN1 may hold promise for TNBC treatment. Funding: This study was supported by grants from the National Natural Science Foundation of China (No. 81872159, 81902607, 81874301), Liaoning Colleges Innovative Talent Support Program (Name: Cancer Stem Cell Origin and Biological Behaviour), Outstanding Scientific Fund of Shengjing Hospital (201803), and Outstanding Young Scholars of Liaoning Province (2019-YQ-10).
Ventricular arrhythmia burden and implantable cardioverter‐defibrillator outcomes in transthyretin cardiac amyloidosis
Brown, Matthew T. , Yalamanchili, Sreeram, Evans, Sean T., Ram, Pradhum , Blank, Evan , Lyle, Melissa , Merchant, Faisal M. , Bhatt, Kunal , Lyle, Melissa A.

Mayo Clinic

Pacing and Clinical Electrophysiology | March 8, 2022 | Volume: 45 | Issue: 4 | Pages: 443-451

10.1111/pace.14458 | PMID 35257420 Get It

AbstractBackgroundAs targeted treatments for amyloid transthyretin cardiomyopathy (ATTR‐CM) are becoming available, we aim to characterize the rates of ventricular arrhythmias (VAs), implantable cardioverter‐defibrillator (ICD) utilization, and their impact on survival.MethodsThis is a retrospective cohort study of 130 patients with ATTR‐CM diagnosed at Emory University's Cardiac Amyloidosis Center between April 2012 and September 2020. VAs were defined as nonsustained or sustained ventricular tachycardia and ventricular fibrillation.ResultsOf 130 patients, 42 had wild‐type disease (wtATTR) and 88 had hereditary variants (hATTR), most commonly Val122Ile (89%). At ATTR‐CM diagnosis, 80 (62%) patients had EF ≤ 40% consistent with systolic heart failure. Of the 69 (53%) patients with documented VAs significantly higher rates occurred among those with EF ≤ 40% compared with EF > 40% (67% vs. 28%, p = .001). Thirty‐two patients (25 hATTR, 7 wtATTR) had primary prevention ICDs implanted. Eight (25%) of these patients received appropriate ICD therapy while two (6%) experienced inappropriate therapy. Comparing patients with EF ≤ 35% with and without ICDs did not reveal any survival difference (3.3 ± 0.5 vs. 2.8 ± 0.4 years, p = .699).ConclusionsHigh rates of VAs and appropriate ICD therapy were found among a unique cohort of largely hereditary ATTR‐CM patients with a high rate of systolic heart failure.
Artificial intelligence and atrial fibrillation
Sehrawat, Ojasav , Kashou, Anthony H. , Noseworthy, Peter A. , Noseworthy, Peter A

Mayo Clinic

Journal of Cardiovascular Electrophysiology | March 8, 2022 | Volume: 33 | Issue: 8 | Pages: 1932-1943

10.1111/jce.15440 | PMID 35258136 Get It

Abstract Background In the context of atrial fibrillation (AF), traditional clinical practices have thus fallen short in several domains, such as identifying patients at risk of incident AF or patients with concomitant undetected paroxysmal AF. Novel approaches leveraging artificial intelligence have the potential to provide new tools to deal with some of these old problems. Aims To discuss the roles of artificial intelligence (AI)‐enabled electrocardiogram (ECG) pertaining to AF, potential roles of deep learning (DL) models in the context of current knowledge gaps, as well as limitations of these models. Materials & Methods An extensive search and review of the currently available literature on the topics. Results One key area where DL models can translate to better patient outcomes is through automated ECG interpretation. Challenges with regards to the benefits and harms of AF screening remain. In this context, a unique model was developed to detect underlying hidden AF from sinus rhythm. Discussion Knowledge gaps remain regarding the best ways to monitor patients with embolic stroke of undetermined source (ESUS) and identifying those who would benefit most from oral anticoagulation. The AI‐enabled AF model is one potential way to tackle this complex problem as it could be used to identify a subset of high‐risk ESUS patients likely to benefit from empirical oral anticoagulation. The role of DL models assessing AF burden from long‐duration ECG data is also discussed as a way of guiding management. There is a trend towards the use of consumer‐grade wristbands and watches to detect AF from photoplethysmography data. However, ECG currently remains the gold standard to detect arrythmias including AF. Lastly, the role of adequate external validation of the models and clinical trials to study true performance is discussed. Conclusion Algorithms using AI to interpret ECGs in various new ways have been developed. While still, much work needs to be done, these technologies have shown enormous potential in a short span of time. With further advancements and continuous research, these novel ways of interpretation may well become part of everyday clinical workflow.
Novel approaches beyond standard immunofluorescence for kidney biopsies
Santoriello, Dominick, Nasr, Samih H., Santoriello, Dominick, Nasr, Samih H.

Mayo Clinic

Current Opinion in Nephrology & Hypertension | March 8, 2022 | Volume: 31 | Issue: 3 | Pages: 221-227

10.1097/mnh.0000000000000783 | PMID 35256574 Get It

Purpose of review Immunofluorescence on frozen tissue (IF-F) utilizing antibodies against immunoglobulin (Ig) heavy and light chains (IgA, IgG and IgM, kappa and lambda) and components of classical and alternative complement pathways (C1q, C3c and C4) is the standard of renal pathology. However, conventional IF-F has limitations, particularly in nephropathies associated with organized and/or monoclonal Ig deposits. This review will discuss new applications of established methods beyond conventional IF-F and recent novel immunohistochemical methods. Recent findings The combined application of paraffin immunofluorescence (IF-P) and IgG subtype staining excluded monotypic deposits in 62–66% of DNA J homolog subfamily B member 9-associated fibrillary glomerulonephritis (FGN) with apparent monotypic deposits by IF-F, whereas IF-P unmasks IgG deposits in a subset of cases of immunotactoid glomerulopathy. A novel IF technique targeting epitopes at the junction of the Ig heavy and light chains was introduced and unmasked polytypic deposits in a subset of glomerulonephritis with apparent monotypic deposits on IF-F. A recent study described the successful application of co-detection by indexing (CODEX) multiplexed IF to visualize more than a dozen target antigens within a single kidney tissue section. Finally, immunohistochemical protocols for detection of the novel antigens in membranous nephropathy have already entered the clinical practice of renal pathology. Summary Novel ancillary techniques in renal pathology have the potential to significantly enhance our ability to evaluate renal biopsies.
Birt-Hogg-Dubé Syndrome Encountered At Rare Lung Disease Clinic In Anhui Province, China
Zhang, Guofeng , Liu, Jinli , Wang, Yushuo , Wang, Yue , Jiang, Xianliang, Peng, Yan, Xiao, Jun , Wei, Wei , Shen, Bing , Yi, Long, Ryu, Jay H. , Ryu, Jay H , Hu, Xiaowen

Mayo Clinic

No container title available | March 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1319752/v1 Get It

Abstract Background: Diagnosis of rare diseases remains a challenge in China. We describe our experience with Birt-Hogg-Dubé syndrome (BHDS) encountered at a Rare Lung Disease Clinic recently established in China.Methods: After the first patient with BHDS was recognized in 2017, a Rare Lung Disease Clinic with a multidisciplinary team of specialists was established. We retrospectively analyzed the data of consecutive patients with BHDS encountered from inception to December 2021.Results: There were 1, 1, 15, 12 and 21 cases with BHDS diagnosed from year 2017 to 2021, respectively. All 50 patients (34 women) were of Han race with a mean age of 47.3 years. The common manifestations were pulmonary cysts (98%), pneumothorax (54%) and skin lesions (68%). Renal cancer was detected in two patients and renal angiomyolipoma in four other patients. The main presentations leading to diagnosis were pneumothorax (42%), family screening (36%) and lung cysts identified on radiologic imaging (20%). The average delay in diagnosis was 8.3 years, and 4.7 years in patients with only pulmonary cysts. The most frequent pathogenic variant was c.1285del/dup on exon 11 (23%) among 44 patients confirmed by genetic testing. Renal cancer has not been found on follow-up surveillance thus far.Conclusions: There has been increasing number of patients with BHDS recognized in China, facilitated by establishment of a Rare Lung Disease Clinic. Pulmonary cysts and pneumothorax were commonly encountered features, but skin lesions appeared to be more prevalent in Chinese subjects than previously reported in other Asian countries.
Sports Climbing and Personality – A Cross-Sectional Study
Steinmetz, Gino, Assman, Mara, Hubert, Jan , Saul, Dominik

Mayo Clinic

No container title available | March 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1365535/v1 Get It

Abstract BackgroundAfter its recent Olympic debut in 2021 climbing continues to gain popularity. Physiological characteristics of climbers have been extensively studied, while the personality of climbers remains poorly understood. Personality research in sports is an established field, predicting long-term success as well as short-term behavior. The recreational athlete’s personality has not been sufficiently examined to date.MethodsWe prospectively analyzed 50 recreational climbers and 50 non-climbing athletes regarding their personality characteristics. We assessed the BMI, the self-reported climbing grade, and the years of climbing experience. To evaluate the personality of recreational climbers and athletes, we used the German version of the Big Five Inventory (BFI-2), which summarizes the personality in five main categories.ResultsRecreational climbers scored significantly higher in conscientiousness than the non-climbing athletes (p = 0.04), there was no significant difference between the other four main personality traits. Female climbers scored significantly higher in conscientiousness than male climbers (p = 0.02), while female athletes scored higher in openness than male athletes (p <0.01). The climbing group displayed a small but significant negative correlation between conscientiousness and BMI (r = -0.39; p <0.01).ConclusionIn conclusion, the personality of recreational climbers and recreational athletes differs in conscientiousness, with the climbers showing higher scores. Regarding gender, we found higher levels of conscientiousness in female climbers and higher openness in female athletes in comparison to their male counterparts. A negative correlation between BMI and conscientiousness of the climbers was detected.